New Delhi, Feb 8 (PTI) Homegrown pharma major Lupin Ltd on Tuesday said it has received approval from the US health regulator for its generic version of arformoterol tartrate inhalation solution, used in treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).

The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of arformoterol tartrate inhalation solution 15 mcg (base)/2 ml, unit-dose vials, the company said in a regulatory filing.

Also Read | Apple Reportedly Considered Adding Face ID to 24-Inch M1 iMac.

It is a generic equivalent of Brovana inhalation solution, 15 mcg/2 ml of Sunovion Pharmaceuticals Inc, it added.

The solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, it added.

Also Read | Signal Now Allows Users To Change Phone Number Without Wiping Out Data.

Arformoterol Tartrate Inhalation Solution is for use by nebulization only, the company said.

Citing IQVIA MAT December 2021 data, Lupin said arformoterol tartrate inhalation solution had an estimated annual sales of USD 251 million in the US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)